Arcellx announces continued robust long-term responses from its cart-ddbcma (anito-cel) phase 1 expansion trial in patients with relapsed or refractory multiple myeloma at ash

-- median duration of response, progression free survival, and overall survival rate not reached with median follow-up after cart-ddbcma (anito-cel) infusion of 26.5 months – -- the estimated median progression free survival by kaplan-meier is 28 months -- -- oral presentation at ash will be on monday, december 11, 2023 at 5 p.m. pt -- -- company to host a live webcast event with an expert panel of clinicians on monday, december 11 at 8 p.m.
ACLX Ratings Summary
ACLX Quant Ranking